A detailed history of Ameritas Advisory Services, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ameritas Advisory Services, LLC holds 14,450 shares of BMY stock, worth $838,100. This represents 0.03% of its overall portfolio holdings.

Number of Shares
14,450
Previous 15,235 5.15%
Holding current value
$838,100
Previous $632,000 18.2%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$39.66 - $51.75 $31,133 - $40,623
-785 Reduced 5.15%
14,450 $747,000
Q2 2024

Jul 29, 2024

SELL
$40.25 - $52.99 $81,667 - $107,516
-2,029 Reduced 11.75%
15,235 $632,000
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $447,845 - $507,769
9,334 Added 117.7%
17,264 $936,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $455,324 - $543,327
-9,392 Reduced 54.22%
7,930 $406,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $576,642 - $644,775
9,961 Added 135.32%
17,322 $1.01 Million
Q2 2023

Jul 25, 2023

SELL
$63.71 - $70.74 $553,639 - $614,730
-8,690 Reduced 54.14%
7,361 $470,000
Q1 2023

Apr 28, 2023

SELL
$65.71 - $74.53 $353,059 - $400,449
-5,373 Reduced 25.08%
16,051 $1.11 Million
Q4 2022

Feb 10, 2023

BUY
$68.48 - $81.09 $127,304 - $150,746
1,859 Added 9.5%
21,424 $1.54 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $43 - $25,971
338 Added 1.76%
19,565 $1.39 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $47,929 - $52,786
660 Added 3.55%
19,227 $1.48 Million
Q1 2022

May 04, 2022

BUY
$61.48 - $73.72 $25,883 - $31,036
421 Added 2.32%
18,567 $1.36 Million
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $973,169 - $1.13 Million
18,146 New
18,146 $1.13 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ameritas Advisory Services, LLC Portfolio

Follow Ameritas Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Advisory Services, LLC with notifications on news.